文献速递白血病

IDH突变急性髓系白血病的当代结局:合并NPM1突变及含维奈克拉方案治疗的影响

Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
PubMed 文献 · Am J Hematol · 2022-09-15

这项回顾性单中心队列研究纳入556例IDH1、IDH2和/或NPM1突变急性髓系白血病患者,分析合并NPM1突变及含维奈克拉方案对疗效和生存的影响。多因素分析显示IDH2突变和IDH野生型/NPM1突变患者死亡风险低于IDH1突变患者;含维奈克拉的低强度方案部分抵消了IDH1突变的不良影响。

要点

  • IDH1突变患者较IDH2突变或IDH野生型/NPM1突变患者更常见高龄、继发性AML、ELN不良风险和不良细胞遗传学。
  • 多因素分析中IDH2突变(HR 0.61)和IDH野生型/NPM1突变(HR 0.65)患者死亡风险低于IDH1突变患者。
  • 含维奈克拉的低强度方案使IDH1突变/NPM1野生型、IDH2突变/NPM1野生型和IDH野生型/NPM1突变患者总生存相似。

核心结论

  • IDH1突变与IDH2突变或NPM1突变AML的结局不同,受合并NPM1突变影响,含维奈克拉方案可部分抵消IDH1突变的不良影响。
  • 鉴于IDH1突变AML不同的生物学和生存,作者认为在该亚组中纳入IDH抑制剂等分子靶向治疗的研究仍有必要。

研究设计与样本

  • 回顾性单中心队列研究,纳入556例IDH1、IDH2和/或NPM1突变的急性髓系白血病患者。
  • IDH1突变组119例,IDH2突变组229例,IDH野生型/NPM1突变组208例。

主要发现

  • IDH1突变患者较IDH2突变或IDH野生型/NPM1突变患者更常见高龄、继发性AML、ELN不良风险和不良细胞遗传学。
  • 多因素分析中,IDH2突变患者较IDH1突变患者死亡风险降低(HR 0.61 [95%CI: 0.43-0.88],P=.007)。
  • 多因素分析中,IDH野生型/NPM1突变患者较IDH1突变患者死亡风险降低(HR 0.65 [95%CI: 0.45-0.94],P=.024)。
  • 含维奈克拉的低强度方案使IDH1突变/NPM1野生型、IDH2突变/NPM1野生型和IDH野生型/NPM1突变患者总生存相似。
  • IDH2突变/NPM1突变患者较IDH2突变/NPM1野生型患者接受IC后生存改善(HR 0.54 [95%CI: 0.2644-1.082],P=.077)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutations occur frequently in newly diagnosed (ND) acute myeloid leukemia (AML) often with co-occurring NPM1 mutations, which may influence treatment outcomes. Detailed analysis of IDH-mutated AML treated with venetoclax and influence of co-occurring NPM1 mutations remains unclear. This retrospective single-center cohort study evaluated clinical and molecular demographics,response and survival, and impact of co-occurring NPM1 mutations in patients with IDH1 or IDH2-mutated AML. 556 patients with IDH1, IDH2, and/or NPM1 mutated AML were included. Patients with IDH1mut AML (N = 119) were more likely to have older age, sAML, ELN-adverse risk disease, and adverse-risk cytogenetics compared to those with IDH2mut (N = 229) or IDHwt /NPM1mut AML (N = 208). In multivariate analysis, patients with IDH2mut (HR 0.61 [95%CI: 0.43-0.88], p value: .007) or IDHwt /NPM1mut (HR 0.65 [95% CI: 0.45-0.94], p value: .024) AML had a decreased risk of death versus IDH1mut AML. Venetoclax-based lower-intensity regimens partially abrogated the detrimental effect of IDH1mut with similar OS observed between IDH1mut /NPM1wt , IDH2mut /NPM1wt , and IDHwt /NPM1mut AML. With regards to the influence of IDHmut /NPM1mut cases, IC improved survival in IDH2mut /NPM1mut versus IDH2mut /NPM1wt AML (HR: 0.54 [95% CI: 0.2644-1.082], p value: .077), while venetoclax-based therapy improved survival in IDH1mut /NPM1mut versus IDH1mut /NPM1wt AML (HR: 0.094 [95% CI: 0.01-0.74], p value: .0056). Differing outcomes were observed in IDH1mut versus IDH2mut or NPM1mut AML which were influenced by co-occurring NPM1 mutations and partially abrogated with venetoclax-based therapy. Given the differing biology and survival in IDH1mut AML, investigations incorporating molecularly targeted therapies such as IDH inhibitors remain warranted in this subgroup.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lachowiez CA, Reville PK, Kantarjian H, et al. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol. 2022. PMID: 36054614. doi:10.1002/ajh.26694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。